State of the art: Chronic kidney disease associated with the hepatitis C virus
DOI:
https://doi.org/10.29059/cie.v2.1.30Keywords:
enfermedad renal crónica, nefropatía asociada a hepatitis C, fisiopatología renal, antivirales de acción directa, virus de la hepatitis CAbstract
Chronic kidney disease associated with the hepatitis C virus (HCV) is a significant extrahepatic manifestation with substantial clinical, pathophysiological, and therapeutic implications. The objective of this narrative review was to comprehensively analyze the available scientific evidence on the mechanisms of kidney damage related to the hepatitis C virus, the main clinical scenarios described, and the impact of treatment with direct-acting antivirals (DAAs). A narrative review of scientific literature published between 2000 and 2024 was conducted, consulting specialized health sciences databases. The findings show that kidney damage associated with the hepatitis C virus occurs through immune-mediated mechanisms and direct damage, leading to various glomerular and tubulointerstitial entities, with clinical manifestations ranging from isolated proteinuria to advanced chronic kidney disease. Current evidence supports the notion that timely treatment with DAAs not only achieves viral eradication but also contributes to stabilizing or improving renal function and preventing the progression of damage. It is concluded that early recognition of these manifestations and timely implementation of antiviral therapies are fundamental to improving renal prognosis and reducing the burden of chronic kidney disease in patients with hepatitis C virus infection.
Downloads
References
Angeletti, A., Cantarelli, C., & Cravedi, P. (2019). HCV‑associated nephropathies in the era of direct‑acting antiviral agents. Frontiers in Medicine, 6, 20. https://doi.org/10.3389/fmed.2019.00020
Bikbov, B., Purcell, C. A., Levey, A. S., Smith, M., Abdoli, A., Abebe, M., … Murray, C. J. L. (2020). Global, regional, and national burden of chronic kidney disease, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. The Lancet, 395(10225), 709–733. https://doi.org/10.1016/S0140‑6736(20)30045‑3
Cacoub, P., Desbois, A. C., Isnard‑Bagnis, C., Rocatello, D., & Ferri, C. (2016). Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. Journal of Hepatology, 65(1 Suppl), S82–S94. https://doi.org/10.1016/j.jhep.2016.06.011
Fabrizi, F., Donato, M. F., Messa, P. G. (2018). Association between hepatitis C virus and chronic kidney disease: A systematic review and meta‑analysis. Annals of Hepatology, 17(3), 364–391. https://doi.org/10.5604/01.3001.0011.7382
Fabrizi, F., Donato, M. F., Nardelli, L., Tripodi, F., Zanoni, F., & Castellano, G. (2024). Hepatitis C virus infection and proteinuria: A systematic review and meta‑analysis. Nefrología, 44(4), 486–495. https://doi.org/10.1016/j.nefroe.2024.01.021
Ferri, C., Giuggioli, D., & Colaci, M. (2017). Renal manifestations of hepatitis C virus. Clinical Liver Disease, 21(3), 487–497. https://doi.org/10.1016/j.cld.2017.03.005
Janczura, J., Jończyk, K., Kalisz, A., Stepień, W., Ilkiewicz, Ł., Bisaga, W., & Wróbel, P. (2025). HCV‑related chronic kidney disease in the era of new direct‑acting antiviral regimens. Egyptian Liver Journal, 15, 45. https://doi.org/10.1186/s43066‑025‑00447‑7
Jiang, M.‑Y., Wu, J.‑Y., & Chi Mei Research Group. (2026). Direct‑acting antivirals and long‑term outcomes in dialysis patients with hepatitis C infection. Kidney International Reports, 11(4), 105795.
Kaartinen, K., Vuoti, S., Honkanen, E., Löyttyniemi, E., Singh, R., & Färkkilä, M. (2021). Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by hepatitis C. PLoS ONE, 16(5), e0251392. https://doi.org/10.1371/journal.pone.0251392
Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. (2022). KDIGO 2022 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney International, 102(6), S129–S205. https://doi.org/10.1016/j.kint.2022.07.013
Martin, P., Awan, A. A., Berenguer, M. C., Bruchfeld, A., Fabrizi, F., Goldberg, D. S., … Jadoul, M. (2022). Executive summary of the KDIGO 2022 clinical practice guideline for hepatitis C in chronic kidney disease. Kidney International, 102(6), 1228–1237. https://doi.org/10.1016/j.kint.2022.07.012
Martin, P., Awan, A. A., Berenguer, M. C., Bruchfeld, A., & KDIGO Work Group. (2023). Executive summary of KDIGO hepatitis C guideline. Kidneys, 12(1), 2–5. https://doi.org/10.22141/2307‑1257.12.1.2023.388
Martinello, M., Solomon, S. S., Terrault, N. A., & Dore, G. J. (2023). Hepatitis C. The Lancet, 402(10407), 1085–1096. https://doi.org/10.1016/S0140‑6736(23)01320‑X
Nevola, R., Rinaldi, L., Zeni, L., Sasso, F. C., Pafundi, P. C., Guerrera, B., … Adinolfi, L. E. (2020). Metabolic and renal changes in patients with chronic hepatitis C after viral eradication with direct‑acting antivirals. JGH Open, 4(4), 713–721. https://doi.org/10.1002/jgh3.12324
Pérez de José, A., Carbayo, J., Pocurull, A., Bada‑Bosch, T., Cases‑Corona, C., Shabaka, A., … Fernandez Lorente, L. (2021). Direct‑acting antiviral therapy improves kidney survival in hepatitis C virus‑associated cryoglobulinaemia. Clinical Kidney Journal, 14(2), 586–592. https://doi.org/10.1093/ckj/sfz178
Rad, N. K., Heydari, Z., Tamimi, A. H., Zahmatkesh, E., Shpichka, A., Barekat, M., … Vosough, M. (2024). Kidney–liver crosstalk: Pathophysiology of their disorders. Cell Journal, 26(2), 98–111. https://doi.org/10.22074/cellj.2023.2007757.1376
Sohal, A., Singh, C., Bhalla, A., Kalsi, H., & Roytman, M. (2024). Renal manifestations of chronic hepatitis C: A review. Journal of Clinical Medicine, 13(18), 5536. https://doi.org/10.3390/jcm13185536
Wang, L., He, Y., Han, C., Zhu, P., Zhou, Y., Tang, R., & He, W. (2025). Global burden of chronic kidney disease and risk factors, 1990–2021. Frontiers in Public Health, 13, 1542329. https://doi.org/10.3389/fpubh.2025.1542329
World Health Organization. (2024). Global hepatitis report 2024. WHO. https://www.who.int/publications/i/item/9789240091672
World Health Organization. (2023). Hepatitis C: Fact sheet. https://www.who.int/news‑room/fact‑sheets/detail/hepatitis‑c
Yau, A. A., Murugapandian, S., Rizvi, A. W., & Gaddy, A. (2024). Viral nephropathies: Core curriculum 2024. American Journal of Kidney Diseases, 84(6), 767–779. https://doi.org/10.1053/j.ajkd.2024.08.004
Downloads
Published
Issue
Section
License
Copyright (c) 2026 https://revistacie.uat.edu.mx/index.php/cie/dautor
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
How to Cite
Accepted 2026-04-05
Published 2026-04-30
